Abstract:Abstract Background Ustekinumab (UST), an anti-IL12/23p40 monoclonal antibody, is now widely used for ulcerative colitis (UC). Meanwhile, there are no established models to predict the efficacy of UST for UC. We previously demonstrated that the machine-leaning approach was useful for finding predictors and developing a prediction tool in vedolizumab (VDZ) treatment for UC (Miyoshi et al. Sci. Rep. 2021). In this study, we aimed to develop a new prediction model for UST in patients with UC. Methods UC patients who started UST as a remission induction therapy in Kyorin University Hospital were enrolled as the training cohort (Cohort 1), and at Toho University Sakura Medical Center were enrolled as the test cohort (Cohort 2). Clinical information of 44 items including age, sex, past/concomitant therapy for UC, clinical and endoscopic activity for UC, blood sample, and so on, in week 0, and clinical activity for UC in week 22 were collected. The outcome was defined as steroid-free clinical remission (SFCR) in week 22. Clinical remission was defined as the Lichtiger index (LI) of four or lower. Patients who terminated UST or needed surgery before week 22 were regarded as not achieving SFCR. Random Forest was used for the clinical data in Cohort 1 to identify the promising predictors to achieve SFCR in week 22. Prediction models were developed with these predictors and their prediction ability was validated in Cohort 2. Results 25 patients (SFCR/non-SFCR=13/12 patients) and 46 patients (SFCR/non-SFCR=27/19 patients) were enrolled as Cohort 1 and Cohort 2, respectively, in this study. First, we examined if a VDZ prediction model that we previously reported could work for predicting the UST efficacy. In Cohort 1, the model showed a positive predictive value (PPV) of 56.3% and a negative predictive value (NPV) of 62.5%. This supports the notion that a prediction model for UST should be different from that for VDZ. From the 44 clinical information, 10 clinical features with the highest contribution to SFCR with UST were detected in Cohort 1. These clinical features included serum albumin, monocyte fraction, height, MCV, total protein, LI, white blood cell count, MCHC, partial Mayo score, and CRP (Figure 1). With these 10 clinical features, the seven prediction models for UST were developed using different algorithms. These models were applied to Cohort 2 to validate the prediction ability. The model that showed the best prediction ability was a support-vector machine polynomial model with PPV 68.8% and NPV 71.4%, respectively. Conclusion We developed a new prediction model for the middle-term efficacy of UST in patients with UC. Further studies are needed to develop a prediction model for each molecular-targeted drug.

Using supervised machine learning approach to predict treatment outcomes of vedolizumab in ulcerative colitis patients

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis

P299 Prediction model for steroid-free clinical remission with vedolizumab at week 22 in patients with Ulcerative Colitis: Machine learning using clinical data at baseline

Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis

Predictors of the efficacy of vedolizumab in patients with ulcerative colitis

P1085 Machine learning to predict the efficacy of ustekinumab for ulcerative colitis

Machine Learning for Predicting Biologic Agent Efficacy in Ulcerative Colitis: An Analysis for Generalizability and Combination with Computational Models

DOP06 Development of simplified scoring system to predict two-year clinical remission of patients with Ulcerative Colitis after treatment with vedolizumab

A metabolomics-driven model for early remission prediction following vedolizumab treatment in patients with moderate-to-severe active ulcerative colitis

A predictive machine-learning model for clinical decision-making in washed microbiota transplantation on ulcerative colitis

Predictive models for endoscopic disease activity in patients with ulcerative colitis: Practical machine learning-based modeling and interpretation

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Development and validation of novel models for the prediction of intravenous corticosteroid resistance in acute severe ulcerative colitis using logistic regression and machine learning

Machine Learning-Based Prediction of Pediatric Ulcerative Colitis Treatment Response using Diagnostic Histopathology

Prediction of anti-TNF therapy failure in ulcerative colitis patients by ensemble machine learning: A prospective study

P1026 Clinical decision support tool for vedolizumab could not predict outcome in ulcerative colitis patients – a retrospective real-life single-centre cohort study

Enhancing Calprotectin's Predictive Power as a Biomarker of Endoscopic Activity in Ulcerative Colitis: A Machine Learning Use Case

Machine Learning‐Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical Trials

Performance of Machine Learning Algorithms for Predicting Disease Activity in Inflammatory Bowel Disease

Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study